Antoine Sakr

Antoine Sakr

Auto-generated profile, based on publicly available information

Antoine Sakr

Loma Linda University Medical Center, Loma Linda, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
JPJay N. Patel
Jay N. Patel
JCJoshua S. Chung
Joshua S. Chung
ASAhmed Seliem
Ahmed Seliem
ASAntoine Sakr
Antoine Sakr
LSLiset Stoletniy
Liset Stoletniy
DADmitry Abramov
Dmitry Abramov

1 July 2019 in Transplantation Proceedings
Verified
Journal Article
Closed access
ASAntoine E. Sakr
Antoine E. Sakr
GFGary E. Fraser
Gary E. Fraser
TDTanya P. Doctorian
Tanya P. Doctorian
HKHyungjin B. Kim
Hyungjin B. Kim
DNDeepika Narasimha
Deepika Narasimha
LSLiset N. Stoletniy
Liset N. Stoletniy

1 January 2021 in Clinical Medicine Insights: Cardiology
Verified
Journal Article
Open access
PDF file
SNShuktika Nandkeolyar
Shuktika Nandkeolyar
TDTanya Doctorian
Tanya Doctorian
GFGary Fraser
Gary Fraser
RRRachel Ryu
Rachel Ryu
CFColleen Fearon
Colleen Fearon
ASAntoine Sakr
Antoine Sakr
Though controversial, the short-duration in-patient use of inotropes in cardiogenic shock (CS) remain an ACC/AHA Class IIa indication, and are frequently used in the initial treatment of CS. We evaluated in-patient mortality and effect on mortality risk of commonly used vasoactive inotropic medications for the medical management of SCAI stage B and C cardiogenic shock patients in a tertiary care cardiac care unit: dobutamine, dopamine, milrinone, and norepinephrine. We retrospectively evaluated 342 patients who received dobutamine, milrinone, dopamine, norepinephrine or a combination of these medications for SCAI stage B and C cardiogenic shock. Cox proportional hazards were used to form longitudinal mortality predictions. Overall in-patient mortality was 18%. Each 1 µg/kg/minute increase in dobutamine independently corresponded to a 15% increase in risk of mortality. High dose dobutamine >3 µg/kg/minute is associated with 3-fold increased risk compared to ⩽3 µg/kg/minute (P < .001). Use of milrinone, norepinephrine, and dopamine were not independently associated with mortality. We demonstrate that the overall in-hospital mortality of SCAI stage B and C cardiogenic shock patients medically managed on inotropes was not in excess of prior studies. Dobutamine was independently associated with mortality, while other vasoactive inotropic medications were not. Inotropes remain a feasible method of managing SCAI stage B and C cardiogenic shock.

1 July 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
DGDennis Grewal
Dennis Grewal
RPRod Partow-Navid
Rod Partow-Navid
DGDante Garcia
Dante Garcia
JCJoshua Coney
Joshua Coney
GFGary Fraser
Gary Fraser
DADmitry Abramov
Dmitry Abramov

28 May 2021 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
SNShuktika Nandkeolyar
Shuktika Nandkeolyar
RRRachel Ryu
Rachel Ryu
AMAdeba Mohammad
Adeba Mohammad
KCKathia Cordero-Caban
Kathia Cordero-Caban
DADmitry Abramov
Dmitry Abramov
ASAntoine Sakr
Antoine Sakr
Inotropes and inopressors are often first-line treatment in patients with cardiogenic shock. We summarize the pharmacology, indications, and contraindications of dobutamine, milrinone, dopamine, norepinephrine, epinephrine, and levosimendan. We also review the data on the use of these medications for acute decompensated heart failure and cardiogenic shock in this article.

1 December 2021 in Transplantation Proceedings
Verified
Journal Article
Closed access
KCKathia Cordero-Caban
Kathia Cordero-Caban
GJGeorge Jolly
George Jolly
ASAntoine Sakr
Antoine Sakr
LSLiset Stoletniy
Liset Stoletniy
DADmitry Abramov
Dmitry Abramov